These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 30984182)

  • 1. The Tumor Immune Contexture of Prostate Cancer.
    Vitkin N; Nersesian S; Siemens DR; Koti M
    Front Immunol; 2019; 10():603. PubMed ID: 30984182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Sun BL
    Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer.
    Jansen CS; Prokhnevska N; Kissick HT
    Urol Oncol; 2019 Aug; 37(8):543-555. PubMed ID: 30446449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
    Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
    Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
    Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer.
    Jafari S; Molavi O; Kahroba H; Hejazi MS; Maleki-Dizaji N; Barghi S; Kiaie SH; Jadidi-Niaragh F
    Cell Mol Life Sci; 2020 Oct; 77(19):3693-3710. PubMed ID: 32006051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-1β Is an Androgen-Responsive Target in Macrophages for Immunotherapy of Prostate Cancer.
    Wang D; Cheng C; Chen X; Wang J; Liu K; Jing N; Xu P; Xi X; Sun Y; Ji Z; Zhao H; He Y; Zhang K; Du X; Dong B; Fang Y; Zhang P; Qian X; Xue W; Gao WQ; Zhu HH
    Adv Sci (Weinh); 2023 Jun; 10(17):e2206889. PubMed ID: 37092583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 Inhibitors for the Treatment of Prostate Cancer.
    Santoni M; Massari F; Cheng L; Cimadamore A; Scarpelli M; Montironi R; Lopez-Beltran A
    Curr Drug Targets; 2020; 21(15):1558-1565. PubMed ID: 32516098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer.
    Melo CM; Vidotto T; Chaves LP; Lautert-Dutra W; Reis RBD; Squire JA
    Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy.
    Prokhnevska N; Emerson DA; Kissick HT; Redmond WL
    Adv Exp Med Biol; 2019; 1210():121-147. PubMed ID: 31900908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review.
    Kim TJ; Koo KC
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ncRNA-mediated overexpression of ubiquitin-specific proteinase 13 contributes to the progression of prostate cancer via modulating AR signaling, DNA damage repair and immune infiltration.
    Cui X; Yu H; Yao J; Li J; Li Z; Jiang Z
    BMC Cancer; 2022 Dec; 22(1):1350. PubMed ID: 36564767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Updated studies on the immunotherapy of prostate cancer].
    Liu J; Li WP; Yang SJ
    Zhonghua Nan Ke Xue; 2022 Apr; 28(4):349-355. PubMed ID: 37477458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.
    Peng S; Hu P; Xiao YT; Lu W; Guo D; Hu S; Xie J; Wang M; Yu W; Yang J; Chen H; Zhang X; Zhu Y; Wang Y; Yang Y; Zhu G; Chen S; Wang J; Zhang B; Chen W; Wu H; Sun Z; Ding T; Zhang H; Yi Z; Liu M; Ren S
    Clin Cancer Res; 2022 Feb; 28(3):552-567. PubMed ID: 34740924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
    Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
    Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study.
    Zhong W; Shen Z; Wu Y; Mao X; Kong J; Wu W
    Front Immunol; 2022; 13():1014981. PubMed ID: 36389756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer.
    Han S; Shi T; Liao Y; Chen D; Yang F; Wang M; Ma J; Li H; Xu Y; Zhu T; Chen W; Wang G; Han Y; Xu C; Wang W; Cai S; Zhang X; Xing N
    J Transl Med; 2023 Mar; 21(1):194. PubMed ID: 36918939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in prostate cancer: new horizon of hurdles and hopes.
    Tsaur I; Brandt MP; Juengel E; Manceau C; Ploussard G
    World J Urol; 2021 May; 39(5):1387-1403. PubMed ID: 33106940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint.
    Tao Z; Xu S; Ruan H; Wang T; Song W; Qian L; Chen K
    Cell Physiol Biochem; 2018; 48(2):801-814. PubMed ID: 30032144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.